Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte antigen 6 complex locus D (LY6D)
- Target
- LY6D
- Molecular classification
- Cell surface protein, Differentiation antigen, Member of Ly-6/uPAR (LU) protein superfamily, GPI (glycosylphosphatidylinositol)-anchored protein
01
Overview
Lymphocyte antigen 6 complex locus D (LY6D) is a member of the Ly6/uPAR superfamily of cell-surface proteins, typically identified as a 22-kDa GPI-anchored antigen. It is highly and selectively expressed in stratified squamous and transitional epithelia and serves as a differentiation marker at critical branch-points of B- and T-lymphocyte development as well as in distinguishing between epithelial and non-epithelial cells. LY6D (also called E48 antigen) is clinically relevant as a cell-surface marker for tumor imaging in head and neck squamous cell carcinoma and is under study for its broader roles in cancer and immune biology. Its restricted tissue expression and cell-surface accessibility make it an attractive target for imaging and potentially therapeutic antibody-based approaches.
- Other names
- E48E48 antigenLy-6DLymphocyte antigen 6DProtein Ly6-D
02
Mechanism of action
Monoclonal anti-E48 antibody: Binds specifically to LY6D antigen on tumor cells, allowing for selective imaging or targeting of squamous cell carcinoma in the head and neck with technetium-99m-labeled E48 IgG or F(ab')2. This enables detection and potentially therapy by targeting cell-surface antigen-expressing malignant cells
03
Biological functions
Immune response: Plays a role in the immune system, particularly as a marker of cell lineage within lymphocytes and epithelial cellsCellular differentiation: Functions as a differentiation marker, notably at branch-points between B- and T-lymphocyte differentiation and between epithelial and non-epithelial cellsPotential involvement in cell adhesion, signaling, and interactions relevant to immune regulation
04
Disease associations
Cancer: Used as a marker and imaging target in head and neck squamous cell carcinoma and potentially in other cancersOther: May have roles in epithelial malignancies and tumorigenesis due to its specific expression in epithelial tissues
05
Safety considerations
As with all antibody-based targeting, potential immunogenicity or off-target effects must be considered, but no prominent unique safety issues are described specifically for LY6D-directed therapeutics in current data
06
Interacting drugs
Radiolabeled monoclonal antibody E48 (for imaging and potentially therapeutic use)
07
Biomarkers
LY6D (E48 antigen) is used as a marker for certain epithelial tumors, especially in the head and neck region, and to identify specific lymphocyte subpopulationsUsed for patient selection in clinical imaging and as a potential measure of disease progression or response
Beyond the preview
Go deeper on Lymphocyte antigen 6 complex locus D (LY6D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lymphocyte antigen 6 complex locus D (LY6D).